Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Cash (2016 - 2025)

Historic Change in Cash for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to -$107.2 million.

  • Theravance Biopharma's Change in Cash fell 36655.64% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 41340.18%. This contributed to the annual value of -$1.7 million for FY2024, which is 9932.41% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Change in Cash is -$107.2 million, which was down 36655.64% from $171.3 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Change in Cash ranged from a high of $331.2 million in Q3 2022 and a low of -$120.4 million during Q4 2022
  • For the 5-year period, Theravance Biopharma's Change in Cash averaged around $4.9 million, with its median value being -$7.5 million (2024).
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 260753.35% in 2023, then soared by 238722.3% in 2025.
  • Over the past 5 years, Theravance Biopharma's Change in Cash (Quarter) stood at -$31.5 million in 2021, then tumbled by 282.59% to -$120.4 million in 2022, then soared by 73.3% to -$32.1 million in 2023, then soared by 144.86% to $14.4 million in 2024, then crashed by 843.14% to -$107.2 million in 2025.
  • Its last three reported values are -$107.2 million in Q3 2025, $171.3 million for Q2 2025, and $72.8 million during Q1 2025.